ONCOMED PHARMACEUTICALS, INC. (NASDAQ:OMED) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On January 5, 2017, OncoMed Pharmaceuticals, Inc. (the Company)
announced selected financial data as of December 31, 2016. The
full text of the press release issued in connection with the
announcement is furnished as Exhibit 99.1 to this Current Report
on Form 8-K and is located on the Companys website at
www.oncomed.com under Investors Press Releases.
The information in Item 2.02 of this Current Report on Form 8-K
(including Exhibit 99.1) shall not be deemed filed for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference
under the Securities Act of 1933, as amended, or the Exchange
Act, except as expressly set forth by specific reference in such
a filing, regardless of any general incorporation language in any
such filing, unless the Company expressly sets forth in such
filing that such information is to be considered filed or
incorporated by reference therein.
Item 7.01. Regulation FD.
On January 5, 2017, the Company issued a press release containing
guidance regarding anticipated fiscal year 2017 events and
milestones. The full text of the press release issued in
connection with the announcement is furnished as Exhibit 99.1 to
this Current Report on Form 8-K and is located on the Companys
website at www.oncomed.com under Investors Press Releases.
The information in Item 7.01 of this Current Report on Form 8-K
(including Exhibit 99.1) shall not be deemed filed for purposes
of Section 18 of the Exchange Act or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference
in such a filing, regardless of any general incorporation
language in any such filing, unless the Company expressly sets
forth in such filing that such information is to be considered
filed or incorporated by reference therein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
Press release |
About ONCOMED PHARMACEUTICALS, INC. (NASDAQ:OMED)
OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company’s product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Anti-DLL4/VEGF Bispecific (OMP-305B83), Anti-RSPO3 (OMP-131R10) and GITRL-Fc. The Company’s Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4), in the Notch signaling pathway. Tarextumab is an antibody that binds to both the Notch2 and Notch3 receptors. Ipafricept is the Company’s Wnt pathway modulator. GITRL-Fc is a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor related protein. ONCOMED PHARMACEUTICALS, INC. (NASDAQ:OMED) Recent Trading Information
ONCOMED PHARMACEUTICALS, INC. (NASDAQ:OMED) closed its last trading session down -0.15 at 8.16 with 195,461 shares trading hands.